. Author manuscript; available in PMC: 2020 Jul 21.

Published in final edited form as: Radiother Oncol. 2009 Nov 11;94(1):76–81. doi: 10.1016/j.radonc.2009.10.001

Table 4.

Comparison of response levels between patients without KRAS mutation and those with the mutations G12D, G12V, and G13D.

Parameter	Level	KRAS mutation								p
		No (n= 49)^a		G12D (n = 15)		G12V (n = 8)		G13D (n = 10)
		n	%	n	%	n	%	n	%
TRG	0	0	0	0	0	0	0	0	0	0.052
	1	4	8	1	7	3	38	0	0
	2	18	38	5	33	3	38	2	20
	3	20	42	7	47	2	24	6	60
	4	6	12	2	13	0	0	2	20
T-level downsizing (uT-yT)	1	20	41	8	54	6	75	2	20	0.11
	1	29	59	7	47	2	25	8	80
UICC downstaging (uUICC-yUICC)	0	24	49	4	27	4	50	1	10	0.08
	1	25	51	11	63	4	50	9	90

For one patient, TRG was not assessable.